^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cyclophosphamide

    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    18h
    Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation (clinicaltrials.gov)
    P1, N=15, Recruiting, C17 Council | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • carboplatin • temozolomide • tamoxifen • cytarabine • cyclophosphamide • etoposide IV • vincristine • topotecan • mesna • thiotepa • Neupogen (filgrastim) • celecoxib oral
    18h
    PALM: Personalising Aotearoa Lupus Medications: investigation of biomarkers for individualisation of therapy (ACTRN12625000698471)
    P=N/A, N=60, Recruiting, Waipapa Taumata Rau, the University of Auckland | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date
    |
    cyclophosphamide
    20h
    Empagliflozin beyond antidiabetic effect: Amelioration of cyclophosphamide-induced testicular toxicity in rats: Orchestrating klotho/Nrf-2/PPAR-γ/NF-κB/ Bax/Bcl-2 cues. (PubMed, Biochem Pharmacol)
    Furthermore, EMPA enhanced testicular tissue survival by decreasing Bcl-2-associated X (Bax) protein, while elevating B-cell lymphoma 2 (Bcl-2) protein, thus reducing caspase-3 expression. Consequentially, EMPA, through antioxidant, anti-inflammatory, and anti-apoptotic effects, could be nominated as a promising candidate against CP-induced gonadal toxicity.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • TNFA (Tumor Necrosis Factor-Alpha) • HMOX1 (Heme Oxygenase 1) • IL10 (Interleukin 10) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • PPARG (Peroxisome Proliferator Activated Receptor Gamma)
    |
    cyclophosphamide
    1d
    Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma (clinicaltrials.gov)
    P3, N=96, Not yet recruiting, Nationwide Children's Hospital
    New P3 trial
    |
    cisplatin • carboplatin • cyclophosphamide
    1d
    RVd and CyBorD therapies remodel B-cell maturation signaling and alter immune and clonal architecture in multiple myeloma. (PubMed, Cancer Biol Ther)
    Although lenalidomide/bortezomib/dexamethasone (RVd) and cyclophosphamide/bortezomib/dexamethasone (CyBorD) are clinically effective, their precise impacts on PC/B-cell maturation remain unclear. RVd responders further downregulated CD56, CD269, and CD329, and increased CD243. These shared and divergent modulations elucidate the molecular underpinnings of RVd and CyBorD efficacy and inform precision regimen selection.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • FGFR3 (Fibroblast growth factor receptor 3) • NOTCH1 (Notch 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • TNFRSF17 (TNF Receptor Superfamily Member 17) • RARA (Retinoic Acid Receptor Alpha) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • PAX5 (Paired Box 5) • KLF4 (Kruppel-like factor 4) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CD200 (CD200 Molecule) • IRF4 (Interferon regulatory factor 4) • CD52 (CD52 Molecule) • PRDM1 (PR/SET Domain 1) • NANOG (Nanog Homeobox) • NES (Nestin) • XBP1 (X-box-binding protein 1) • CD81 (CD81 Molecule) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2) • SLAMF7 (SLAM Family Member 7) • SIGLEC9 (Sialic Acid Binding Ig Like Lectin 9)
    |
    lenalidomide • bortezomib • cyclophosphamide
    1d
    A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL (clinicaltrials.gov)
    P2, N=39, Active, not recruiting, University of Rochester | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq)
    1d
    Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer (clinicaltrials.gov)
    P3, N=559, Completed, Sun Yat-sen University | Recruiting --> Completed
    Trial completion
    |
    docetaxel • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide
    1d
    A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV) (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Cabaletta Bio | Phase classification: P1 --> P1/2
    Phase classification
    |
    cyclophosphamide • fludarabine IV
    1d
    RMS13: Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy (clinicaltrials.gov)
    P2, N=115, Active, not recruiting, St. Jude Children's Research Hospital | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    Avastin (bevacizumab) • sorafenib • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • dactinomycin • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • dexrazoxane
    1d
    Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant (clinicaltrials.gov)
    P1/2, N=16, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    1d
    Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=18, Recruiting, University of Washington | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    2d
    MUKEight: Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma. (clinicaltrials.gov)
    P2, N=112, Completed, University of Leeds | Unknown status --> Completed | Trial completion date: Jan 2021 --> Jan 2025
    Trial completion • Trial completion date
    |
    lenalidomide • bortezomib • cyclophosphamide • Ninlaro (ixazomib) • thalidomide